October 1, 2019
Sobi buys Dova Pharmaceuticals for $915 million
Swedish Orphan Biovitrum (Sobi) said Monday it will Dova Pharmaceuticals for an upfront payment of $27.50 per share in cash and, one non-tradeable Contingent Value Right (CVR), with an additional $1.50 for shareholders upon approval of Doptelet for use in Chemotherapy-Induced Thrombocytopenia (CIT) by the US Food and Drug Administration (FDA).